ImportantLLY
Explain this story: Lilly reports Foundayo data. Eli Lilly and Company stock costs EUR 1,021.90 ahead of results
Eli Lilly's oral GLP-1 medicine, Foundayo, demonstrated a 57.00% reduction in predicted 10-year type 2 diabetes risk and an 18.00% reduction in predicted cardiovascular disease risk after 72 weeks at a 17.2 mg dose. These findings, from post-hoc analyses of the ATTAIN-1 Phase 3 study, provide new data points for the company's oral obesity-medicine strategy. Investors are anticipating the third-quarter 2026 earnings call on October 29, 2026, to assess the continued growth of the company's revenue and the commercial adoption of its GLP-1 products.
OtherAD HOC NEWSSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Eli Lilly's oral GLP-1 medicine, Foundayo, demonstrated a 57.00% reduction in predicted 10-year type 2 diabetes risk and an 18.00% reduction in predicted cardiovascular disease risk after 72 weeks at a 17.2 mg dose. These findings, from post-hoc analyses of the ATTAIN-1 Phase 3 study, provide new data points for the company's oral obesity-medicine strategy. Investors are anticipating the third-quarter 2026 earnings call on October 29, 2026, to assess the continued growth of the company's revenue and the commercial adoption of its GLP-1 products.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Oct 2, 2026, 11:14 ET · on this site +1h 17m